1. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. (2nd June 2020) Authors: Pollock, Richard F.; Colaone, Fabien; Guardiola, Laura; Shergill, Suki; Brennan, Victoria K. Journal: Journal of medical economics Issue: Volume 23:Number 6(2020) Page Start: 593 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. (2nd October 2016) Authors: Muduma, Gorden; Odeyemi, Isaac; Pollock, Richard F. Journal: Journal of medical economics Issue: Volume 19:Number 10(2016) Page Start: 995 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. (2nd July 2020) Authors: Pollock, Richard F.; Muduma, Gorden Journal: Journal of medical economics Issue: Volume 23:Number 7(2020) Page Start: 751 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Issue 2 (1st February 2019) Authors: Pollock, Richard F.; Muduma, Gorden Journal: Expert review of hematology Issue: Volume 12:Issue 2(2019) Page Start: 129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. Issue 3 (4th March 2021) Authors: Pollock, Richard F.; Brennan, Victoria K.; Shergill, Suki; Colaone, Fabien Journal: Expert review of anticancer therapy Issue: Volume 21:Issue 3(2021) Page Start: 341 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. (July 2014) Authors: Muduma, Gorden; Odeyemi, Isaac; Pollock, Richard F. Journal: Journal of medical economics Issue: Volume 17:Number 7(2014) Page Start: 520 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Correction to: Lane et al., Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. (4th May 2018) Authors: Lane, Ws; Weatherall, James; Gundgaard, Jens; Pollock, Richard F. Journal: Journal of medical economics Issue: Volume 21:Number 5(2018) Page Start: 542 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. (2nd July 2016) Authors: Bruhn, David; Martin, Alan A.; Tavares, Ruben; Hunt, Barnaby; Pollock, Richard F. Journal: Journal of medical economics Issue: Volume 19:Number 7(2016) Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Issue 2 (1st February 2020) Authors: Pollock, Richard F.; Biggar, Patrick Journal: Expert review of hematology Issue: Volume 13:Issue 2(2020) Page Start: 187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. (1st February 2018) Authors: Lane, Wendy S.; Weatherall, James; Gundgaard, Jens; Pollock, Richard F. Journal: Journal of medical economics Issue: Volume 21:Number 2(2018) Page Start: 144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗